Selfemra Side Effects

Generic name: fluoxetine

Medically reviewed by Drugs.com. Last updated on Feb 5, 2024.

Note: This document provides detailed information about Selfemra Side Effects associated with fluoxetine. Some dosage forms listed on this page may not apply specifically to the brand name Selfemra.

Applies to fluoxetine: oral capsule, oral capsule delayed release, oral solution, oral syrup, oral tablet.

Serious side effects of Selfemra

Along with its needed effects, fluoxetine (the active ingredient contained in Selfemra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fluoxetine:

Other side effects of Selfemra

Some side effects of fluoxetine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to fluoxetine: compounding powder, oral capsule, oral delayed release capsule, oral solution, oral tablet.

General adverse events

The most commonly reported side effects included insomnia, asthenia, and headache.^[Ref]

Nervous system

• Very common (10% or more): Headache (up to 21%), somnolence (up to 17%), tremor (up to 13%), dizziness (up to 11%)
• Common (1% to 10%): Amnesia, hyperkinesia, paresthesia/sensory disturbances, taste perversion/dysgeusia
• Uncommon (0.1% to 1%): Abnormal gait, acute brain syndrome, ataxia, balance disorder, central nervous system (CNS) depression, CNS stimulation, dyskinesia, hyperkinesia, hypertonia, hyperesthesia, incoordination, memory impairment, migraine, myoclonus, neuralgia, neuropathy, syncope, vascular headache, vertigo
• Rare (0.01% to 0.1%): Abnormal electroencephalogram, cerebral embolism, cerebral ischemia, circumoral paresthesia, convulsion/seizures, delusions, dysarthria, dystonia, extrapyramidal syndrome, foot drop, hyperesthesia, neuritis, paralysis, parosmia, reflexed decreased, serotonin syndrome (neuroleptic malignant syndrome-like effects), stupor, taste loss
• Very rare (less than 0.01%): Mild intensity headache
• Frequency not reported: Autonomic instability, coma, hyperreflexia, hypersomnia, neuromuscular aberrations, sedation
• Postmarketing reports: Cerebrovascular accident, movement disorders, tardive dyskinesia, worsening of preexisting movement disorders^[Ref]

Potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs as monotherapy, but particularly with concomitant use of other serotonergic drugs and drugs that impair the metabolism of serotonin.^[Ref]

Psychiatric

• Very common (10% or more): Insomnia (up to 33%), anxiety (up to 15%), nervousness (up to 14%)
• Common (1% to 10%): Abnormal dreams, agitation, disturbance in attention, emotional lability, hostility, hypomania, mania, personality disorder, restlessness, sleep disorder, tension, thinking abnormal
• Uncommon (0.1% to 1%): Akathisia, apathy, bruxism, depersonalization, elevated mood, euphoria, intentional overdose, manic reaction, neurosis, paranoid reaction, psychomotor hyperactivity, psychosis, suicidal thoughts and behavior, suicide attempt
• Rare (less than 0.1%): Aggression, antisocial reaction, delusions, dysphemia, hallucinations, panic attacks
• Frequency not reported: Activation syndrome, anger, complete suicide, depression, depression suicidal, early morning awakening, initial insomnia, intense dreams, intentional self-injury, mental status changes, middle insomnia, morbid thoughts, nightmares, self-injurious ideation and behavior, sleep disturbances, suicidal ideation
• Postmarketing reports: Confusion, discontinuation/withdrawal symptoms, irritability, violent behaviors^[Ref]

Antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. An increased risk of suicidal thinking and behavior in children, adolescents, and young adults (aged 18 to 24 years) with major depressive disorder (MDD) and other psychiatric disorders has been reported with short-term use of antidepressant drugs.

Adult and pediatric patients receiving antidepressants for MDD, as well as for psychiatric and nonpsychiatric indications, have reported symptoms that may be precursors to emerging suicidality, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Causality has not been established.^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 29%), diarrhea (up to 18%), dry mouth (up to 12%)
• Common (1% to 10%): Abdominal pain, constipation, dyspepsia, flatulence, gastrointestinal disorder, vomiting
• Uncommon (0.1% to 1%): Aphthous stomatitis, buccoglossal syndrome, colitis, dysphagia, eructation, esophagitis, gastritis, gastroenteritis, gastrointestinal (GI) hemorrhage, glossitis, gum hemorrhage, hyperchlorhydria, increased salivation, melena, mouth ulceration, stomach ulcer, stomatitis
• Rare (less than 0.1%): Acute abdominal syndrome, bloody diarrhea, duodenal ulcer, enteritis, esophageal pain, esophageal ulcer, fecal incontinence, hematemesis, intestinal obstruction, pancreatitis, peptic ulcer, salivary gland enlargement, stomach ulcer hemorrhage, tongue edema
• Frequency not reported: Anal/esophageal/gastric/upper and lower GI/hemorrhoidal/peritoneal/rectal hemorrhage, bleeding esophageal varices, enterocolitis, esophageal/duodenal/gastric ulcer hemorrhage, GI bleeding, gingival/mouth bleeding, hematochezia, hemorrhagic diarrhea/diverticulitis/gastritis, intraabdominal hemorrhage^[Ref]

A study of 26,005 antidepressant users has reported 3.6 times more upper GI bleeding episodes with the use of SSRIs relative to the population who did not receive antidepressant medications. Upper gastrointestinal tract bleeding was observed in 3.9 times more frequently in patients receiving this drug.^[Ref]

Respiratory

• Very common (10% or more): Rhinitis (up to 23%), pharyngitis (up to 11%), yawn/yawning (up to 11%)
• Common (1% to 10%): Epistaxis, sinusitis
• Uncommon (0.1% to 1%): Asthma, dyspnea, hiccup, hyperventilation
• Rare (less than 0.1%): Apnea, atelectasis, decreased cough, emphysema, hemoptysis, hypoventilation, hypoxia, larynx edema, lung edema, pneumothorax, pulmonary events (inflammatory processes of varying histopathology and/or fibrosis), stridor
• Frequency not reported: Increased cough, interstitial lung disease, pneumonitis
• Postmarketing reports: Eosinophilic pneumonia, pulmonary embolism, pulmonary hypertension^[Ref]

Other

• Very common (10% or more): Asthenia/fatigue (up to 21%),
• Common (1% to 10%): Accidental injury, chills, ear pain, feeling jittery, fever, lethargy, thirst, tinnitus
• Uncommon (0.1% to 1%): Abortion, face edema, feeling abnormal, feeling hot/cold, malaise
• Rare (less than 0.1%): Deafness, hypothermia, mucosal hemorrhage
• Frequency not reported: Growth delay, hyperthermia, pain
• Postmarketing reports: Malignant hyperthermia^[Ref]

Metabolic

• Very common (10% or more): Anorexia (up to 17%)
• Common (1% to 10%): Decreased appetite, increased appetite, weight loss
• Uncommon (0.1% to 1%): Dehydration, gout, hypercholesterolemia, hyperlipemia, hypokalemia
• Rare (less than 0.1%): Alcohol intolerance, alkaline phosphatase increased, blood sugar level changes, diabetic acidosis, diabetes mellitus, hyperkalemia, hyperuricemia, hypocalcemia, hyponatremia
• Frequency not reported: Decreased alkaline phosphatase levels
• Postmarketing reports: Hypoglycemia^[Ref]

Decreased weight gain has been observed in association with use in children and adolescents.^[Ref]

Genitourinary

• Very common (10% or more): Decreased libido/loss of libido (up to 11%)
• Common (1% to 10%): Abnormal ejaculation/ejaculation disorder, dysmenorrhea, erectile dysfunction, gynecological bleeding, impotence, micturition disorder, urinary frequency
• Uncommon (0.1% to 1%): Albuminuria, amenorrhea, anorgasmia, breast enlargement, breast pain, dysuria, female lactation, fibrocystic breast, hematuria, impaired urination, increased libido, leukorrhea, menorrhagia, metrorrhagia, nocturia, pelvic pain, polyuria, sexual dysfunction (occasionally persisting after treatment discontinuation), urinary incontinence, urinary retention, vaginal hemorrhage
• Rare (less than 0.1%): Breast engorgement, glycosuria, hypomenorrhea, uterine hemorrhage, uterine fibroids enlarged
• Frequency not reported: Delayed ejaculation, delayed sexual maturation, dysfunctional uterine bleeding, ejaculation dysfunction/failure, galactorrhea, genital hemorrhage, menometrorrhagia, orgasmic dysfunction, polymenorrhea, postmenopausal hemorrhage, premature ejaculation, retrograde ejaculation, uterine cervix hemorrhage, vaginal bleeding after drug withdrawal
• Postmarketing reports: Enlarged clitoris, pollakiuria^[Ref]

Urinary retention and galactorrhea have been reported with other SSRIs.

The estimates of the incidence of untoward sexual experience and performance may underestimate their actual incidence, partly because patients and physicians may be reluctant to discuss this issue. In placebo-controlled clinical trials ejaculation disorder (primarily ejaculation delay) was reported as a treatment-emergent side effect at an incidence of 6% and at least twice the incidence in placebo-treated male patients.^[Ref]

Immunologic

• Very common (10% or more): Flu syndrome (up to 12%)
• Common (1% to 10%): Infection
• Rare (less than 0.1%): Herpes zoster^[Ref]

Cardiovascular

• Common (1% to 10%): Chest pain, flushing/hot flush, hypertension, palpitation, QT-interval prolongation, vasodilatation
• Uncommon (0.1% to 1%): Angina pectoris, arrhythmia, congestive heart failure, generalized edema, hypotension, myocardial infarct, peripheral edema, postural hypotension
• Rare (less than 0.1%): Bradycardia, extrasystoles, heart block, pallor, peripheral vascular disorder, phlebitis, shock, thrombophlebitis, thrombosis, vasculitis, vasospasm, ventricular arrhythmia, ventricular extrasystoles, ventricular fibrillation
• Frequency not reported: Labile blood pressure, tachycardia
• Postmarketing reports: Atrial fibrillation, heart arrest, torsades de pointes/torsades de pointes-type arrhythmias^[Ref]

Patients have developed QT prolongation of at least 450 msec.^[Ref]

Dermatologic

• Common (1% to 10%): Pruritus, rash, sweating/hyperhidrosis, urticaria
• Uncommon (0.1% to 1%): Acne, alopecia, cold sweat, contact dermatitis, ecchymosis, eczema, increased tendency to bruise, maculopapular rash, skin discoloration, skin ulcer
• Rare (less than 0.1%): Epidermal necrolysis/toxic epidermal necrolysis, erythema multiforme, furunculosis, hirsutism, petechia, photosensitivity reaction, psoriasis, purpura, purpuric rash, seborrhea, Stevens Johnson syndrome/Lyell syndrome
• Frequency not reported: Erythema, exfoliative rash, heat rash, erythematous rash, follicular rash, generalized rash, macular rash, morbilliform rash, papular rash, pruritic rash, vesicular rash, umbilical erythema rash
• Postmarketing reports: Erythema nodosum, exfoliative dermatitis, thrombocytopenic purpura^[Ref]

Alopecia was usually reversible.^[Ref]

Ocular

• Common (1% to 10%): Abnormal vision, vision blurred
• Uncommon (0.1% to 1%): Conjunctivitis, dry eyes, mydriasis, photophobia
• Rare (less than 0.1%): Blepharitis, diplopia, exophthalmos, glaucoma, hyperacusis, iritis, scleritis, strabismus, visual field defect
• Frequency not reported: Increased intraocular pressure
• Postmarketing reports: Cataract, oculogyric crises, optic neuritis^[Ref]

Musculoskeletal

• Common (1% to 10%): Arthralgia, muscle twitching/twitching
• Uncommon (0.1% to 1%): Arthritis, bone pain, bursitis, leg cramps, tenosynovitis
• Rare (less than 0.1%): Arthrosis, chondrodystrophy, creatine phosphokinase increased, myalgia, myasthenia, myopathy, osteomyelitis, osteoporosis, rheumatoid arthritis
• Frequency not reported: Back pain, bone fractures^[Ref]

Epidemiological studies, primarily in patients aged 50 years or older, have shown an increased risk of bone fractures in patients receiving SSRIs or TCAs.^[Ref]

Hypersensitivity

• Common (1% to 10%): Allergic reaction
• Rare (less than 0.1%): Anaphylactic/anaphylactoid reaction, angioedema, serum sickness^[Ref]

Hepatic

• Uncommon (0.1% to 1%): Abnormal liver function tests, cholelithiasis
• Rare (less than 0.1%): Biliary pain, cholecystitis, hepatitis, idiosyncratic hepatitis, liver fatty deposits, transaminases increased, gamma glutamyltransferase increased
• Frequency not reported: Abnormal hepatic function, aggravation of hepatic damage, cholestatic jaundice, hepatic failure/necrosis^[Ref]

Hematologic

• Rare (less than 0.1%): Blood dyscrasias, hypochromic anemia, iron deficiency anemia, leukopenia, lymphedema, lymphocytosis, neutropenia, thrombocytopenia
• Postmarketing reports: Aplastic anemia, eosinophilia, immune-related hemolytic anemia, pancytopenia^[Ref]

Endocrine

• Uncommon (0.1% to 1%): Hypothyroidism
• Rare (less than 0.1%): Inappropriate secretion of antidiuretic hormone
• Frequency not reported: Gynecomastia, hyperprolactinemia^[Ref]

Renal

• Uncommon (0.1% to 1%): Albuminuria
• Rare (less than 0.1%): Blood urea nitrogen (BUN) increased, kidney pain, oliguria
• Postmarketing reports: Kidney failure^[Ref]

Frequently asked questions

• SSRIs vs SNRIs - What's the difference between them?
• Is Prozac (fluoxetine) safe for dogs?
• Prozac vs Zoloft - What are the Differences & Similarities?
• What are some common side effects of antidepressants?
• Taking fluoxetine, what can I use for a bad cough from cold or strep throat?

Further information

Selfemra side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer